Clinical-stage biopharmaceutical company developing genetically and pharmacologically validated therapies for cardiovascular and metabolic diseases
Clinical-stage biopharmaceutical company developing genetically and pharmacologically validated therapies for cardiovascular and metabolic diseases. Its pipeline includes protein-based therapeutics and late-stage clinical programs; the company was launched by Blackstone Life Sciences in 2019.